[go: up one dir, main page]

WO2010059916A2 - Préparation de docétaxel - Google Patents

Préparation de docétaxel Download PDF

Info

Publication number
WO2010059916A2
WO2010059916A2 PCT/US2009/065283 US2009065283W WO2010059916A2 WO 2010059916 A2 WO2010059916 A2 WO 2010059916A2 US 2009065283 W US2009065283 W US 2009065283W WO 2010059916 A2 WO2010059916 A2 WO 2010059916A2
Authority
WO
WIPO (PCT)
Prior art keywords
docetaxel
formula
compound
solvent
ether
Prior art date
Application number
PCT/US2009/065283
Other languages
English (en)
Other versions
WO2010059916A3 (fr
Inventor
Rajasekhar Kadaboina
Sekhar Munaswamy Nariyam
Lankeshwara Rao Matti
Sridhar Vasam
Siva Reddy Makireddy
Shravan Kumar Komati
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Priority to EP09828277A priority Critical patent/EP2358693A4/fr
Publication of WO2010059916A2 publication Critical patent/WO2010059916A2/fr
Publication of WO2010059916A3 publication Critical patent/WO2010059916A3/fr
Priority to US13/112,165 priority patent/US20110275841A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Definitions

  • aspects of the present invention relate to docetaxel and processes for preparing docetaxel, including process-related intermediates. Aspects of the present invention also relate to processes for preparing substantially pure docetaxel and its intermediates.
  • Docetaxel an antineoplastic agent belonging to the taxoid family, has a chemical name (2R,3S)-N-carboxy-3-phenylisosehne, N-te/t-butyl ester, 13-ester with 5 ⁇ -20-epoxy-1 ,2 ⁇ ,4,7 ⁇ ,10 ⁇ ,13 ⁇ -hexahydroxytax-11 -en-9-one 4-acetate 2- benzoate, and in its anhydrous form can be represented by structural Formula I.
  • Docetaxel is useful in the treatment of the malignant neoplasms, such as solid tumors, and other malignancies.
  • U.S. Patent No. 4,814,470 discloses docetaxel, its stereoisomeric forms, pharmaceutical compositions containing docetaxel, and their use in the treatment of acute leukemia and solid tumours.
  • U.S. Patent No. 5,476,954 discloses a process for preparing docetaxel that involves:
  • step (b) treating the compound obtained in step (a) with formic acid to give 4- acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20-epoxy-1-hydroxy-9-oxo-7 ⁇ ,10 ⁇ -bis[(2,2,2- trichloroethoxy) carbonyloxy]-11 -taxen-13 ⁇ -yl(2R,3S)-3-amino-2-hydroxy-3-phenyl propionate, and purifying the product by flash chromatography using dichloromethane/methanol as eluent;
  • step (c) converting the compound obtained from step (b) to 4-acetoxy-2 ⁇ - benzoyloxy-5 ⁇ ,20-epoxy-1-hydroxy-9-oxo-7 ⁇ ,10 ⁇ -bis[(2,2,2- trichloroethoxy)carbonyloxy]-11 -taxen-13 ⁇ -yl (2R,3S)-3-tert-butoxycarbonylamino- 2-hydroxy-3-phenylpropionate, by the action of di-te/f-butyl dicarbonate in the presence of an inorganic or organic base; and
  • step (d) converting the compound obtained in step (c) to docetaxel by deprotection of the hydroxyl protecting group, 2,2,2-trichloroethoxycarbonyl, from the 7 ⁇ and 10 ⁇ positions using zinc in the presence of acetic acid and methanol.
  • step (b) As disclosed in U.S. Patent No. 5,476,954 (“the '954 process") requires a reaction time of about 4.5 hours, and using excess molar equivalents of di-te/f-butyl dicarbonate (about 16 equivalents) in step (c) as required in the '954 process leads to the formation of increased amounts (up to 5%) of each of the related impurities I and Il and formation of related impurity III in amounts more than 5%.
  • Table 1 The structures of the three principal impurities formed in the '954 process are shown in Table 1.
  • step (d) of the '954 process results in the formation of increased levels of the impurities shown in Table 2.
  • U.S. Patent No. 5,686,623 discloses a process for preparing 4-acetoxy-2 ⁇ - benzoyloxy-5 ⁇ ,20-epoxy-1 -hydroxy-9-oxo-7 ⁇ ,10 ⁇ -bis(2,2,2- trichloroethoxycarbonyloxy)-tax-11 -en-13- ⁇ -yl(4S,5R)-3-te/t-(butoxycarbonyl)-2,2- dimethyl-4-phenyl-1 ,3-oxazolidine-5-carboxylate, by reacting 4-acetoxy-2 ⁇ - benzoyloxy-5 ⁇ ,20-epoxy-1 ,13 ⁇ -dihydroxy-9-oxo-7 ⁇ ,10 ⁇ -bis[(2,2,2- trichloroethoxy)carbonyloxy]-11-taxene with (4S,5S)-3-te/t-butoxycarbonyl-2,2- dimethyl-4-phenyl-1.S-oxazolidine- ⁇ -carboxylic acid in the presence of DCC,
  • U.S. Patent No. 6,197,980 discloses a process for preparing docetaxel by reacting 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20-epoxy-1 ⁇ -hydroxy-7 ⁇ ,10 ⁇ -bis[(2,2,2- trichloroethoxy) carbonyloxy]-9-oxo-11 -taxen-13 ⁇ -yl (2R,3S)-3-t- butoxycarbonylamino-3-phenyl-2-hydroxy propionate with zinc and acetic acid in the presence acetonitrile.
  • U.S. Patent No. 5,616,739 discloses a process for preparing 4-acetoxy-2 ⁇ - benzoyloxy-5 ⁇ ,20-epoxy-1 ⁇ ,7 ⁇ ,10 ⁇ -trihydroxy-9-oxo-11 -taxen-13 ⁇ -yl (2R,3S)-3- amino-2-hydroxy-3-phenylpropionate by reacting 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20- epoxy-i ⁇ -hydroxy-Z ⁇ .i O ⁇ -bis ⁇ -trichloroethoxyJcarbonyloxyl- ⁇ -oxo-H -taxen- 13 ⁇ -yl (4S,5R)-3-(2,2,2-trichloroethoxycabonyl)2,2-dimethyl-4-phenyl-5- oxazolidine carboxylate with zinc and glacial acetic acid in the presence of ethyl acetate.
  • the reaction conditions as disclosed in various disclosures for preparing docetaxel and its intermediates may result in the generation of increased level of process related impurities.
  • These impurities may be, for example, starting materials, by-products of the reaction, products of side reactions, or degradation products.
  • the removal of these impurities at each stage of the process using expensive purification techniques, such as flash chromatography or column purification in multiple stages may result in lower yield, which is not suitable for an industrial-scale process.
  • the present invention relates to docetaxel and processes for preparing docetaxel, including process-related intermediates.
  • the present invention also related to processes for preparing substantially pure docetaxel and its intermediates thereof.
  • the present invention provides process for preparing docetaxel, which process comprises: a) reacting 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20-epoxy-1 -hydroxy-9-oxo-
  • the present invention provides process for purifying the intermediate compound of Formula IV, which process comprises: a) providing a solution of the compound of formula IV in an organic solvent; b) combining the solution of step a) with an anti-solvent; c) isolating the compound of formula IV; and d) optionally repeating steps (a)-(c) to obtain a desired purity.
  • the present invention further provides processes for preparing docetaxel, an embodiment comprising reacting an intermediate compound of formula IV,
  • the present invention further provides processes for preparing substantially pure docetaxel, embodiments comprising any of I, II, and II, or combinations thereof:
  • Fig. 1 illustrates an X-ray powder diffraction (XRPD) pattern of docetaxel, as prepared in Example 11.
  • XRPD X-ray powder diffraction
  • the present invention provides processes for preparing docetaxel, embodiments comprising: a) reacting 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20-epoxy-1 -hydroxy-9-oxo- 7 ⁇ ,10 ⁇ -bis[(2,2,2-tri-chloroethoxy)carbonyloxy]-11 -taxen-13 ⁇ -yl (4S,5R)-3-terf- butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate of formula II,
  • Step (a) involves the reaction of the compound of formula Il with formic acid at temperatures about 20 to 40 0 C for less than 2 hours.
  • step (a) The amount of formic acid used in step (a) is about 5-30 ml_, per gram of the compound of Formula II.
  • the process of step (a) may be carried out at temperatures about 20-40 0 C.
  • step (a) conducting step (a) using 5-30 ml_ of formic acid, per gram of the compound of formula II, and at temperatures about 20-40°C will not only facilitate completion of the reaction in less than 2 hours, but also reduce the formation of related impurities, particularly the principal impurities, i.e., impurities I and II, to amounts less than about 1 %. In embodiments, the process results in amounts of these principal impurities less than about 0.5%.
  • the reaction mass may be diluted with an organic solvent and optionally with water and/or brine solution, and stirred for a suitable time.
  • the organic solvents used include, but are not limited to: esters such as for example ethyl acetate, butyl acetate, isopropyl acetate and the like; ketones such as methyl isobutyl ketone and the like; ethers such methyl te/t-butyl ether, dimethoxyethane, diethoxyethane and the like; and any combinations thereof.
  • the organic layer may be separated and may optionally be washed with water and saturated bicarbonate solution. The process may be repeated if desired.
  • the obtained reaction mass may optionally be concentrated before proceeding to the next reaction step.
  • Step (b) involves reacting 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20-epoxy-1 - hydroxy- ⁇ -oxo-Z ⁇ .iO ⁇ -bis ⁇ -thchloroethoxyJcarbonyloxyl-H-taxen-I S ⁇ - yl(2R,3S)-3-amino-2-hydroxy-3-phenylpropionate ⁇ i.e., the reaction product of step (a)) with 1 to 1.5 molar equivalents of di-te/f-butyl dicarbonate.
  • the quantity of di-te/t-butyl dicarbonate in step (b) may be about 1.2 molar equivalents, per molar equivalent of 4-acetoxy-2 ⁇ -benzoyloxy-5 ⁇ ,20-epoxy-1 - hydroxy-9-oxo-7 ⁇ ,10 ⁇ -bis[(2,2,2-thchloroethoxy)carbonyloxy]-11-taxen-13 ⁇ -yl (2R,3S)-3-amino-2-hydroxy-3-phenylpropionate.
  • the reaction of step (b) may be achieved in a bi-phasic medium.
  • the bi- phasic medium for step (b) may be obtained by charging water to the reaction mass or organic layer obtained in step (a).
  • the pH of the resulting reaction mass is adjusted using a base, e.g., sodium bicarbonate, either as a solid or its saturated solution or with an organic base for e.g., thethylamine, diispropylethylamine and the like.
  • a base e.g., sodium bicarbonate
  • the pH of the reaction mass may be adjusted to a range of about 7-9. In embodiments, the pH of the reaction mass may be adjusted to about 7.5-8.5 using solid sodium bicarbonate.
  • Step (b) may be carried out at temperatures about 20-40 0 C. In embodiments, step (b) may be carried out at temperatures about 25-30 0 C.
  • the organic layer may be separated and optionally washed with water.
  • the organic layer obtained may be concentrated to about 3 ml_ per gram of the compound of formula Il used, under high vacuum and at temperatures about 40-50°C.
  • the compound of formula IV may be precipitated by cooling the reaction mass to 25-30 0 C and by adding a suitable anti-solvent, such as but not limited to alkanes, including, for example, n-heptane, n-hexane, cyclohexane, and the like.
  • the obtained solid may be separated using conventional techniques known in the art. After separation, the solid may optionally be washed, e.g., with an anti- solvent, and may optionally be further dried by techniques known in the art. The drying may be carried out at temperatures of about 35-70 0 C, optionally under reduced pressure, for any time periods necessary for obtaining a desired purity.
  • the compound of formula IV contains the related impurity (Impurity III) in amounts less than about 1 %.
  • Step (c) involves converting the compound of formula IV to docetaxel.
  • the compound of formula IV obtained in step (b) may be converted to docetaxel using a process known in the art or by the process described hereinbelow.
  • a) providing a solution of the compound of formula IV in an organic solvent; b) combining the solution with an anti-solvent; c) isolating the compound of formula IV; and d) optionally repeating steps (a)-(c) to obtain a desired purity.
  • Purification step (a) involves providing a solution of the compound of formula IV in an organic solvent.
  • the organic solvents which may be used for providing a solution of the compound of formula IV include, but are not limited to: esters such as for example ethyl acetate, butyl acetate, isopropyl acetate and the like; nitriles such as acetonithle, propionitrile and the like; halogenated alkanes such as dichloromethane, chloroform and the like; and any combinations thereof.
  • the organic solvent may comprise acetonitrile.
  • the concentration of the compound of formula IV in the organic solvent may generally range from about 0.01 to about 1 g/mL. However the concentration of the compound of formula IV in the organic solvent selected is not critical, although the quantity of solvent employed is usually kept to a minimum to avoid excessive product losses during the crystallization of the solute (i.e., the compound of formula IV).
  • the solution of the compound of formula IV in the organic solvent may be prepared at temperatures ranging from about 25-75 0 C. Depending on the quantity of solvent used, the compound of formula IV may dissolve at a temperature of about 25-35 0 C, or the solution may need to be heated to elevated temperatures.
  • Purification step (b) involves combining the solution of step (a) with an anti- solvent.
  • Useful anti-solvents include, but are not limited to: ethers, such as, for example, diethyl ether, diisopropyl ether, methyl te/f-butyl ether, and the like; and any combinations thereof.
  • the anti-solvent may comprise diisopropyl ether.
  • Suitable temperatures for purification step (b) may range from about 0- 50 0 C, or from about 25-35°C.
  • Purification step (c) involves isolating the compound of formula IV.
  • the solid formed after purification step (b) may be separated using conventional techniques known in the art.
  • One skilled in the art may appreciate that there are many ways to separate a solid from the mixture. For example, it may be separated by filtration by gravity or suction, centrifugation, decantation, and the like.
  • the solid may optionally be washed, e.g., with a suitable anti-solvent.
  • the solid obtained is washed with petroleum ether.
  • the isolated solid may optionally be further dried by using conventional techniques.
  • the drying may be carried out at temperatures of about 35-70 0 C, optionally under reduced pressure.
  • the drying may be carried out for any time periods necessary for obtaining a desired purity, such as about 1 to about 25 hours, or longer.
  • the compound of formula IV typically has a purity greater than or equal to about 92%, or greater than or equal to about 98%, and contains less than about 0.5% of each of the impurities I, II, and III, as determined using high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • Purification step (d) involves optionally repeating purification steps (a) through (c) to obtain a desired purity. Purification steps (a) through (c) may optionally be repeated to get a substantially pure compound of formula IV having purity greater than or equal to about 95%, or greater than or equal to about 98%, as determined using HPLC.
  • the present invention includes the compound of formula IV substantially free of its isomeric or related impurities.
  • the term "substantially free of its isomeric or the related impurities" as used herein shall be understood to mean comprising isomeric or related impurities in an amount less than about 2%, or less than about 0.5%, or less than about 0.15%, or less than about 0.05%, of the identified compound.
  • aspects of the present invention further provide processes for preparing docetaxel, embodiments comprising reacting an intermediate compound of formula IV,
  • step (a) may be about 1-30 molar equivalents, per mole of the compound of formula IV. In embodiments, about 16 moles of zinc, per mole of the compound of formula IV, may be used.
  • the organic acid used in the reaction may comprise acetic acid, propionic acid, butanoic acid, oxalic acid, and the like. In embodiments, acetic acid is used.
  • the amount of the organic acid used in the reaction may range from about 1-5 mL, per gram of the compound of formula IV. In embodiments, about 1 mL of acetic acid, per gram of the compound of formula IV, may be used.
  • the ketone solvents that may be used in the process of step (a) include, but are not limited to, acetone, methyl isobutyl ketone, ethyl methyl ketone, and the like. In embodiments, acetone is used.
  • the amount of ketone solvent used in the reaction may range from about 1-40 ml_, per gram of the compound of formula IV. In embodiments, about 20 ml_, or about 30 ml_, of acetone, per gram of the compound of formula IV, may be used.
  • the process may be carried out at temperatures of about 25°C to about the reflux temperature of the solvent used. In embodiments, it may be carried out at temperatures about 30-50 0 C. It has been found that reacting the compound of formula IV with zinc in the presence of an organic acid and a ketone solvent gives docetaxel with increased purity, as compared to the prior processes that result in docetaxel having a content of impurities V and Vl greater than about 5-6%.
  • reaction mass may optionally be filtered through media such as a bed of diatomaceous earth, and washed with the ketone solvent.
  • the obtained filtrate may optionally be concentrated to a minimum volume, for example, 1-5 ml_ per gram of the compound of formula IV, and used in the next level of purification or extracted into another organic solvent, and/or may be isolated by precipitation to give docetaxel.
  • Docetaxel may be precipitated from the solution by addition of an anti- solvent.
  • Useful anti-solvents include, but are not limited to: alkanes, such as, for example, n-heptane, n-hexane, cyclohexane, and the like; ethers, such as, for example, diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 1 ,4-dioxane, dimethoxyethane, methyl te/f-butyl ether, and the like; water; and any combinations thereof.
  • water is used as an anti-solvent.
  • Suitable temperatures for solid crystallization may range from about 0 0 C to about 50 0 C, or from about 25°C to about 35°C.
  • the obtained solid may be separated using conventional techniques known in the art. After separation, the solid may optionally be washed with an anti- solvent.
  • the isolated solid may optionally be further dried by techniques known in the art.
  • the drying may be carried out at temperatures of about 35°C to about 70 0 C, optionally under reduced pressure, for any time periods necessary for obtaining a desired purity.
  • Docetaxel can be obtained from the present invention in a high yield of more than about 95%, with a high purity of more than about 90%.
  • the docetaxel obtained may optionally be further purified according to a process known in the art, or by column chromatography, or by crystallization processes, as per the processes disclosed in the present application.
  • aspects of the present invention further provides processes for preparing substantially pure docetaxel, embodiments comprising one or more of I, II, and III.
  • Docetaxel obtained from any synthetic methods can be used as a starting material.
  • Docetaxel (such as having purity about 85% or less) can be purified by crystallization of the present invention.
  • Docetaxel is dissolved in a solvent comprising a nitrile solvent, such as acetonitrile, propionitrile, and the like.
  • docetaxel is dissolved in a solvent mixture of acetonitrile and dichloromethane.
  • docetaxel may dissolve at temperatures about 25 0 C to 75 0 C, or the mixture may need to be heated to elevated temperatures. b) Combining the solution of step a) with an ether.
  • step a) The solution of docetaxel obtained in step a) is combined with an ether solvent such as diethyl ether, diisopropyl ether, methyl te/t-butyl ether, and the like, or any combinations thereof, for precipitation.
  • Suitable temperatures for solid precipitation may range from about 0 0 C to about 50 0 C, or from about 25°C to about 35°C.
  • the obtained precipitate may be separated using conventional techniques known in the art and the solid may optionally be washed with a suitable ether solvent, and the isolated solid may optionally be further dried or the wet solid may be used directly for the next level of purification.
  • purification of docetaxel is carried out by providing a solution of docetaxel in a solvent mixture of dichloromethane and acetonitrile, and precipitating a solid by combining the solution with diisopropyl ether.
  • Docetaxel is combined with: a ketone solvent such as acetone, methyl isobutyl ketone, methyl ethyl ketone, and the like: a halogenated hydrocarbon solvent such as dichloromethane, chloroform, and the like; an ester solvent such as ethyl acetate, n-propyl acetate, n-butyl acetate and the like; and any mixtures thereof to provide a solution or suspension. Depending on the solvent and its quantity used, docetaxel may dissolve at temperatures about 25 0 C or higher. b) Adding toluene to the solution or suspension obtained.
  • a ketone solvent such as acetone, methyl isobutyl ketone, methyl ethyl ketone, and the like
  • a halogenated hydrocarbon solvent such as dichloromethane, chloroform, and the like
  • an ester solvent such as ethyl acetate, n-propyl
  • the solution or suspension of docetaxel is combined with toluene and the obtained suspension can be stirred for about 30 minutes to about 2 hours, or longer.
  • the amount of toluene used may range from about 5 ml_ to about 30 ml_, per gram of the starting docetaxel.
  • Isolating crystalline docetaxel The formed solid may be separated using conventional techniques known in the art and the solid may optionally be washed with toluene or an ether and the isolated solid may optionally be further dried or the wet compound may be progressed directly to the next level of purification.
  • the purification of docetaxel is carried out by providing a solution of docetaxel in methyl isobutyl ketone, and precipitating the compound by adding toluene.
  • the purification of docetaxel is carried out by providing a solution of docetaxel in methyl ethyl ketone, and precipitating the compound by adding toluene.
  • the above crystallization processes can result in docetaxel having purity greater than or equal to about 98%, as determined using HPLC.
  • a solution of docetaxel can be provided by dissolving docetaxel in a ketone solvent, such as acetone, methyl isobutyl ketone, methyl ethyl ketone, and the like. Solutions of docetaxel can be provided at temperatures about 25°C to about 45°C, or higher. b) Adding ether to the solution.
  • a ketone solvent such as acetone, methyl isobutyl ketone, methyl ethyl ketone, and the like.
  • Solutions of docetaxel can be provided at temperatures about 25°C to about 45°C, or higher.
  • Suitable ethers that can used in the process of the present invention for precipitation include, but are not limited to, diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 1 ,4-dioxane, dimethoxyethane, methyl te/f-butyl ether, and the like.
  • diisopropyl ether is used to precipitate docetaxel.
  • the obtained suspension can be stirred for about 30 minutes to about 2 hours, or longer, to increase the extent of solid formation.
  • Isolating crystalline docetaxel Isolating crystalline docetaxel.
  • the obtained solid precipitate may be isolated using conventional techniques known in the art and the solid may optionally be washed with a suitable solvent such as n-hexane, n-heptane, or cyclohexane.
  • a suitable solvent such as n-hexane, n-heptane, or cyclohexane.
  • the wet solid may optionally be further dried
  • the above processes of the present invention result in substantially pure docetaxel, having purity greater than or equal to about 99%, or greater than or equal to about 99.5%, and each of the impurities, viz. Impurity I, Impurity II, , Impurity III, Impurity IV, Impurity V, Impurity Vl, Impurity VII and Impurity VIII, Impurity IX (2',3'-epidocetaxel), Impurity X (2'-epidocetaxel), Impurity X (2'-epidocetaxel), Impurity Xl (10-oxo- docetaxel), Impurity XII (7-epi-docetaxel), Impurity XIII (10-oxo-7-epidocetaxel), may be present at less than about 0.15% as determined using HPLC.
  • Buffer 1.36 g of potassium dihydrogen phosphate dissolved in 1000 ml_ of purified water, pH adjusted to 3+0.05 using dilute phosphoric acid, and filtered through a 0.45 ⁇ m porosity membrane.
  • Wavelength of detection 230 nm by UV.
  • Injection volume 20 ⁇ l_.
  • Wavelength of detection 230 nm by UV.
  • Injection volume 20 ⁇ l_.
  • Buffer 1.36 g of potassium dihydrogen phosphate dissolved in 1000 ml_ of purified water, pH adjusted to 3+0.05 using dilute phosphoric acid, and filtered through a 0.45 ⁇ m porosity membrane.
  • Eluent B filtered acetonitrile.
  • Wavelength of detection 230 nm by UV.
  • Injection volume 20 ⁇ L.
  • Diluent acetonitrile.
  • the filtrate is washed with 500 mL of aqueous saturated NaHCO3 solution, then with 1000 mL of water.
  • the organic layer is concentrated to 300 mL at 45°C under vacuum.
  • the organic layer is filtered to remove a dicyclohexylurea byproduct and then is washed with 100 mL of dichloromethane.
  • the filtrate is added slowly to 1600 mL of n-heptane in a round bottom flask at 25-30 0 C over 40-60 minutes, and the mass is stirred for 1 hour.
  • the obtained suspension is filtered and the solid is washed with 200 mL of n-heptane.
  • the solid is dried at 50 0 C for 4 hours under high vacuum, to afford 122.6 g of the title compound. Yield: 93.7%.
  • Impurities by HPLC Unidentified (at -0.84 RRT): 0.36%; Impurity I: 0.22%; Impurity II: 0.26%; Unidentified (at -0.99 RRT): 0.11 %; Unidentified (at -1.01 RRT): 0.54%; Impurity VIII: 1.09%; and Impurity III: 0.99%.
  • Impurities by HPLC 10-oxo DCT: 0.33%; 7-epi DCT: 0.40%; 10-oxo-7-epi DCT: 0.19%; Impurity Vl: 1.60%; and Impurity V: 2.10%. Purification using column chromatography.
  • a column is packed with silica gel (230-400 mesh, 487.5 g) in 20% ethyl acetate in petroleum ether (1000 mL).
  • Docetaxel (19.5 g, 92.14% purity) is dissolved in dichloromethane (39 mL) at 40-45 0 C, cooled to 25-35°C, and charged to the column.
  • the column is eluted with a mixture of ethyl acetate and petroleum ether (1000 mL of 20% ethyl acetate in petroleum ether, 1000 mL of 40% ethyl acetate in petroleum ether, and 8 L of 45% ethyl acetate in petroleum ether).
  • the desired pure fractions are collected by monitoring with TLC and pooled to give a purified fraction.
  • the purified fraction is concentrated at 45-50°C under vacuum to a volume of 55-65 mL, then cooled to 25-30 0 C and combined with petroleum ether (390 mL). The mixture is stirred for 30 minutes at 25-30°C and filtered under vacuum. The wet solid is washed with petroleum ether (40 mL) and dried under high vacuum to give purified docetaxel.
  • the concentrated filtrate is loaded into the column and the column is eluted with 1000 ml_ of petroleum ether and mixtures of ethyl acetate in petroleum ether (600 ml_ of 20% ethyl acetate in petroleum ether, 600 ml_ of 40% ethyl acetate in petroleum ether, and 4000 ml_ of 45% ethyl acetate in petroleum ether).
  • the desired pure fractions are collected, combined, and distilled under vacuum at 48°C until 30 ml_ remains.
  • 50 ml_ of dichloromethane is added to the residue and distilled at 47°C under vacuum until 30 ml_ remains.
  • 450 ml_ of petroleum ether is added to the residue and stirred for 60 minutes.
  • a column is packed with 125 g of 230-240 mesh silica gel in 300 mL of petroleum ether and the column is washed with petroleum ether two to three times for close packing.
  • a portion of the filtrate from above (25 mL) is loaded into the column and eluted first with 300 mL of petroleum ether, and then with mixtures of ethyl acetate and petroleum ether (300 mL of 20% ethyl acetate in petroleum ether, 300 ml_ of 40% ethyl acetate in petroleum ether, and 2000 ml_ of 45% ethyl acetate in petroleum ether).
  • the product-containing fractions are collected and distilled under vacuum at 48°C to a volume of 10-20 ml_.
  • the distillation residue is added to 45 ml_ of petroleum ether over 15 minutes and the suspension is stirred for 30 minutes.
  • the suspension is filtered and the solid is washed with 10 ml_ of petroleum ether and suction dried for 30 minutes to give 2.2 g of purified docetaxel.
  • a portion of the filtrate obtained above (35 ml_, corresponding to 5 g of the compound of Formula IV) is added to 500 ml_ of water and stirred for 1 hour.
  • the solid is filtered and washed with 10 ml_ of water.
  • the solid is suction dried for 1 hour to give 3 g of docetaxel.
  • a column is packed with 75 g of 230-400 mesh silica gel in 200 ml_ of petroleum ether.
  • the docetaxel (3 g) is dissolved in 24 mL of dichloromethane at 40 0 C and then loaded into the column.
  • the column is eluted with mixtures of ethyl acetate and petroleum ether (250 ml_ of 20% ethyl acetate in petroleum ether, 500 ml_ of 40% ethyl acetate in petroleum ether, and 1600 ml_ of 45% ethyl acetate in petroleum ether).
  • Product-containing fractions are collected and concentrated to less than 15 ml_ under vacuum at 48°C.
  • 45 mL of petroleum ether is added to the residue and stirred for 15 to 30 minutes at 27°C.
  • the suspension is filtered and the solid is suction dried for 30 minutes to give 2.16 g of purified docetaxel. Yield: 72%.
  • Purity by HPLC 99.1 1 %.
  • a portion of the organic layer (-1250 mL) is distilled to obtain 150 mL of concentrate and then mixed with 600 mL of n-heptane.
  • the mass is distilled to obtain 250 mL of concentrate, which is combined with 500 mL of n-heptane.
  • the mass is distilled to obtain 600 mL of concentrate, which is stirred for 1 hour at 25- 30°C and filtered.
  • the solid is washed with 100 mL of n-heptane, suction dried for 15 minutes, and dried under high vacuum at 45-50 0 C for about 4 hours.
  • Impurities by HPLC Impurity I: 0.06%; Impurity II: not detected; 2',3'-epi docetaxel: 0.02%; 2'-epi docetaxel: 0.03%; 10-oxo docetaxel: 0.01 %; 10-oxo-7-epi docetaxel: not detected; Impurity V: not detected; Impurity Vl: not detected.
  • Part Il treatment :
  • a portion of the organic layer (-625 mL) is distilled to obtain 75 mL of concentrate and then mixed with 125 mL of acetonitrile. The mass is distilled to obtain 50 mL of concentrate, which is mixed with 375 mL of diisopropyl ether and stirred for 1 hour at 25-30 0 C. The solid is filtered, washed with 50 mL of n- heptane, suction dried under vacuum for 15 minutes, and dried under high vacuum at 45-50 0 C for about 4 hours.
  • Impurities by HPLC 10-deacetylbaccatin III: not detected; Impurity I: 0.05%; Impurity II: not detected; 2',3'-epi docetaxel: not detected; 2'-epi docetaxel: 0.19%; 10-oxo docetaxel: 0.09%; 7-epi docetaxel: 0.77%; formula IV: not detected; 10-oxo-7-epi docetaxel: not detected; Impurity V: 0.83%; Impurity Vl: 0.39%.
  • Impurities by HPLC Impurity I: 0.07%; Impurity II: not detected; Impurity V: not detected; Impurity Vl: not detected; 2',3'-epi docetaxel: 0.09%; 2'-epi docetaxel: not detected; 10-oxo docetaxel: 0.16%; 7-epi-docetaxel: 0.21 %; 10- oxo-7-epi docetaxel: 0.06%.
  • Impurities by HPLC Impurity I: 0.03%; Impurity II: not detected; Impurity V: not detected; Impurity Vl: not detected; 2',3'-epi docetaxel: 0.02%; 2'-epi docetaxel: 0.03%; 10-oxodocetaxel: 0.1 %; 7-epi-docetaxel: 0.04%; 10-oxo-7-epi docetaxel: not detected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur le docétaxel et sur des procédés pour préparer le docétaxel, comprenant des intermédiaires liés au procédé. La présente invention porte également sur des procédés pour préparer du docétaxel et des intermédiaires sensiblement purs.
PCT/US2009/065283 2008-11-20 2009-11-20 Préparation de docétaxel WO2010059916A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09828277A EP2358693A4 (fr) 2008-11-20 2009-11-20 Préparation de docétaxel
US13/112,165 US20110275841A1 (en) 2008-11-20 2011-05-20 Preparation of docetaxel

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2884/CHE/2008 2008-11-20
IN2884CH2008 2008-11-20
US14821909P 2009-01-29 2009-01-29
US61/148,219 2009-01-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/112,165 Continuation US20110275841A1 (en) 2008-11-20 2011-05-20 Preparation of docetaxel

Publications (2)

Publication Number Publication Date
WO2010059916A2 true WO2010059916A2 (fr) 2010-05-27
WO2010059916A3 WO2010059916A3 (fr) 2010-07-15

Family

ID=42198817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065283 WO2010059916A2 (fr) 2008-11-20 2009-11-20 Préparation de docétaxel

Country Status (3)

Country Link
US (1) US20110275841A1 (fr)
EP (1) EP2358693A4 (fr)
WO (1) WO2010059916A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539186A (ja) * 2013-11-22 2016-12-15 ジアンスー タスリー ディイ ファーマスーティカル カンパニー リミテッドＪｉａｎｇｓｕ Ｔａｓｌｙ Ｄｉｙｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． タキサン化合物、その調製方法およびその使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012028037A2 (pt) 2010-05-03 2016-08-02 Teikoku Pharma Usa Inc formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN115650882A (zh) * 2022-11-14 2023-01-31 肇庆学院 一种多西他赛杂质及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
EP0764643A1 (fr) * 1994-06-09 1997-03-26 Daiichi Pharmaceutical Co., Ltd. Derive de desacetoxytaxol
US5917062A (en) * 1997-11-21 1999-06-29 Indena S.P.A Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
US6881852B2 (en) * 2002-02-05 2005-04-19 Dabur India Limited Process of purification of paclitaxel and docetaxel
US7247738B2 (en) * 2002-05-07 2007-07-24 Dabur India Limited Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6956123B2 (en) * 2003-03-17 2005-10-18 Natural Pharmaccuticals, Inc. Purification of taxanes and taxane mixtures using polyethyleneimine-bonded resins
KR100816491B1 (ko) * 2005-11-17 2008-03-24 주식회사 삼양제넥스 탁산류 함유 물질로부터 13-디하이드록시바카틴 ⅲ 및10-디아세틸파클리탁셀의 추출 및 정제 방법
EP2001874A4 (fr) * 2006-03-21 2010-04-07 Reddys Lab Ltd Dr Polymorphes de docétaxel et procédés
WO2008051465A2 (fr) * 2006-10-20 2008-05-02 Scinopharm Singapore Pte, Ltd. Procédé servant à fabriquer du docétaxel anhydre cristallin
WO2009006590A2 (fr) * 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Procédés de préparation de docétaxel et de polymorphes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2358693A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539186A (ja) * 2013-11-22 2016-12-15 ジアンスー タスリー ディイ ファーマスーティカル カンパニー リミテッドＪｉａｎｇｓｕ Ｔａｓｌｙ Ｄｉｙｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． タキサン化合物、その調製方法およびその使用
US10253007B2 (en) 2013-11-22 2019-04-09 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Taxanes compounds, preparation method therefor, and uses thereof

Also Published As

Publication number Publication date
EP2358693A4 (fr) 2012-04-18
EP2358693A2 (fr) 2011-08-24
US20110275841A1 (en) 2011-11-10
WO2010059916A3 (fr) 2010-07-15

Similar Documents

Publication Publication Date Title
EP1018510B1 (fr) L'isolation et purification de la paclitaxel et des autres taxanes par l'industrielle chromatographie du pression basse préparative sur une colonne de la résine polymérique
JP5593342B2 (ja) ドセタキセルの製造方法
JP2009533330A (ja) ドセタキセルの多形体およびプロセス
WO2010059916A2 (fr) Préparation de docétaxel
KR100847331B1 (ko) 도세탁셀의 제조방법 및 이에 사용되는 중간체
JP2004521948A (ja) 種々のタキサン類の選択的ヒドラジン分解による１０−ｄａｂｉｉｉの効率的な製造方法
RU2326876C2 (ru) Способ получения паклитаксела
KR100921036B1 (ko) 탁산유도체의 제조방법 및 이에 사용되는 중간체
CN106748853B (zh) 一种（s）-邻氯苯甘氨酸甲酯盐酸盐的制备方法
KR100868116B1 (ko) 도세탁셀·모노프로필렌글라이콜 내포화합물 및 이의제조방법
KR101009467B1 (ko) 도세탁셀의 합성에 유용한 탁산 유도체 및 그 제조방법
RU2437875C2 (ru) Полиморфы доцетаксела и способы их получения
CA2258066C (fr) Separation et purification de paclitaxel et d'autres taxanes voisines par chromatographie industrielle de preparation a faible pression sur une colonne en resine polymere
JP5870197B2 (ja) タキサン誘導体の製造方法
WO2009137084A2 (fr) Processus de préparation des taxanes et de leurs intermédiaires
HK1108317B (en) Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
HK1140490B (en) Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
EP1712552A1 (fr) Semisynthese de preparation de 10-deacetyl-n-debenzoyl paclitaxel
CN107848990A (zh) 紫杉醇和多烯紫杉醇的侧链前体的制造方法
EP1647552A1 (fr) Semisynthese de preparation de 10-deacetyl-n-debenzoyl-paclitaxel
MXPA00000318A (en) Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09828277

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009828277

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4035/CHENP/2011

Country of ref document: IN